-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-J&J Reports 77% Response Rate For Rybrevant Faspro In First-Line Head And Neck Cancer

路透·10/25/2026 18:26:53

請登錄查看新聞詳情